Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov 20;29(33):4373-80.
doi: 10.1200/JCO.2010.33.6446. Epub 2011 Oct 17.

Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women

Eunjung Lee  1 , Roberta McKean-Cowdin, Huiyan Ma, Darcy V Spicer, David Van Den Berg, Leslie Bernstein, Giske Ursin
Affiliations

Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women

Eunjung Lee et al. J Clin Oncol. .

Abstract

Purpose: Triple-negative breast cancers (TNBCs) are tumors with low or no expression of estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2. These tumors have a poor prognosis, remain a clinical challenge, and are more common among women with BRCA1 mutations. We tested whether there are distinguishing features of TNBC after BRCA1 mutation status has been taken into account.

Patients and methods: We sequenced BRCA1 and BRCA2 genes in a population-based sample of 1,469 patients with incident breast cancer age 20 to 49 years from Los Angeles County (California). Information on tumor receptor status was available for 1,167 women. Clinical, pathologic, and hormone-related lifestyle characteristics were compared across patient subgroups defined by BRCA1 mutation status and triple-negative receptor status.

Results: Forty-eight percent of BRCA1 mutation carriers had TNBC compared with only 12% of noncarriers. Within BRCA1 mutation carriers, as well as within noncarriers, triple-negative receptor status was associated with younger age at diagnosis and higher tumor grade. Among women without a BRCA1 mutation, we observed that women with TNBC had higher premenopausal body mass index and earlier age at first full-term pregnancy than those with non-TNBC. Age at menarche and other reproductive factors were not associated with triple-negative status regardless of BRCA1 mutation status. Within BRCA1 mutation carriers, Ashkenazi Jewish women were about five times more likely to have TNBC than non-Ashkenazi Jewish women.

Conclusion: Our results suggest that among BRCA1 mutation carriers, as among noncarriers, there are unique characteristics associated with the triple-negative subtype. The findings in Ashkenazi Jewish BRCA1 mutation carriers should be confirmed.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Description of participants of the Women's Learning the Influence of Family and Environment (LIFE) study who were included in the current analyses.
See this image and copyright information in PMC

Comment in

References

    1. Hudis CA. Trastuzumab: Mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39–51. - PubMed
    1. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators: Mechanisms of action and application to clinical practice. N Engl J Med. 2003;348:618–629. - PubMed
    1. Reis-Filho JS, Tutt AN. Triple negative tumours: A critical review. Histopathology. 2008;52:108–118. - PubMed
    1. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. Cancer. 2007;109:1721–1728. - PubMed
    1. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–2334. - PubMed

Publication types